Prosecution Insights
Last updated: October 04, 2026
Application No. 18/872,328

SOLID FORMS OF RXFP1 MODULATORS

Non-Final OA §112
Filed
Dec 06, 2024
Priority
Jun 07, 2022 — provisional 63/365,970 +1 more
Examiner
ISMAIL, REHANA
Art Unit
1625
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
MITSUBISHI TANABE PHARMA Corporation
OA Round
1 (Non-Final)
76%
Grant Probability
Favorable
1-2
OA Rounds
1y 8m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 76% — above average
76%
Career Allowance Rate
75 granted / 99 resolved
+15.8% vs TC avg
Strong +35% interview lift
Without
With
+34.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
34 currently pending
Career history
131
Total Applications
across all art units

Statute-Specific Performance

§101
4.6%
-35.4% vs TC avg
§103
29.1%
-10.9% vs TC avg
§102
21.4%
-18.6% vs TC avg
§112
27.3%
-12.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 99 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Current Status of 18/872,328 This Office Action is in response to the amended claims of 07/16/2026. Claims 1-4, 6, 8, 10-11, 13-15, and 17-24 are currently amended; and claim 5 is original. Claims 1-6, 8, 10-11, 13-15, and 17-24 are examined in this office action. Priority Effective filing date is 06/07/2022. Information Disclosure Statement The information disclosure statement (IDS) was submitted on 03/11/2025. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 22 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The term “substantially” in claim 22 is a relative term which renders these claim 22 indefinite. The term “substantially” is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. As drafted, the term “substantially” renders the metes and bounds of claims 22 undefined (hence rendering claims 22 indefinite) since the artisan has no idea by which objective standard “substantially” should be measured. Please delete “substantially” from the claims to render moot this rejection. Conclusion Claim 22 is rejected. Claims 1-6, 8, 10-11, 13-15,17-21 and 23-24 are allowable as written. Examiner did not find prior art for independent claims 1, 18 and 19. Close art of Lars et.al (WO 2022/122773) teaches the Compound (I) (page 628, claim 65) but does not teach the amorphous or crystal form of Compound(I). Moreover Lars et.al. have publication date of 16th June 2022, after the effective filing date of the instant application. Therefore, Lars is a close art but not a prior art. US patent No 11,667,602 is not a double patenting art because the claims are not directed to amorphous or crystalline form of compound(I). Any inquiry concerning this communication or earlier communications from the examiner should be directed to Rehana Ismail whose telephone number is (703)756-4776. The examiner can normally be reached Monday-Friday 9:00am-5:00pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew D Kosar can be reached at (571)272-913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /R.I./Examiner, Art Unit 1625 /JOHN S KENYON/Primary Patent Examiner, Art Unit 1625
Read full office action

Prosecution Timeline

Dec 06, 2024
Application Filed
Sep 08, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12741932
ISOTOPIC THYROMIMETIC COMPOUNDS
3y 9m to grant Granted Sep 22, 2026
Patent 12729208
INHIBITOR OF APOPTOSIS (IAP) PROTEIN ANTAGONISTS
3y 10m to grant Granted Sep 08, 2026
Patent 12709607
POTENT AND SELECTIVE IRREVERSIBLE INHIBITORS OF IRAK1
3y 11m to grant Granted Aug 18, 2026
Patent 12686692
KRAS G12D INHIBITORS
3y 4m to grant Granted Jul 21, 2026
Patent 12673044
METHODS OF TREATING BORDERLINE PERSONALITY DISORDER
4y 9m to grant Granted Jul 07, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
76%
Grant Probability
99%
With Interview (+34.8%)
3y 6m (~1y 8m remaining)
Median Time to Grant
Low
PTA Risk
Based on 99 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month